DRUG
Retatrutide
Administered SC
A Study of Retatrutide (LY3437943) in Participants Without Type 2 Diabetes Who Have Obesity or Overweight
Status
Active, not recruiting
Phase
Phase 3
Enrollment
600
Locations
35
Results
Not posted
Publications
0
Study summary
What the protocol is testing.
The purpose of this study is to investigate the efficacy and safety of different retatrutide dose escalation schemes in participants without type 2 diabetes who have obesity or overweight. Participation in the study will last about 113 weeks.
Interventions
Treatment arms and agents.
Timeline
From registration to results.
First posted
Jan 22, 2026
Study start
Jan 24, 2026
Primary completion
Oct 2028
Study completion
Nov 2028
Results posted
Not reported
Registry updated
Jun 9, 2026
Outcomes
What the study measures.
Primary outcomes
Percent Change from Baseline in Body Weight
Time frame · Baseline, Week 104
Secondary outcomes
Change from Baseline in Waist Circumference
Time frame · Baseline, Week 104
Percent Change from Baseline in Triglycerides
Time frame · Baseline, Week 104
Change from Baseline in Systolic Blood Pressure
Time frame · Baseline, Week 104
Percent Change from Baseline in High Sensitivity C-Reactive Protein
Time frame · Baseline, Week 104
Change from Baseline in Impact of Weight on Quality of Life-Lite-Clinical Trials (IWQOL-Lite-CT) Total Score
Time frame · Baseline, Week 104
Overall Treatment Satisfaction with Medication for Obesity (TS-MO) Scores
Time frame · Week 104
Pharmacokinetics (PK): Steady state Average Trough PK Concentration
Time frame · Baseline through Week 104
Eligibility
Who can take part.
- Minimum age
- 18 Years
- Maximum age
- Not reported
- Sex
- ALL
- Healthy volunteers
- No
Inclusion Criteria: * Have a Body Mass Index (BMI) at screening * ≥ 30 kilogram per square meter (kg/m2) OR * ≥ 27 kg/m2 with presence of at least one of the following weight-related conditions at screening: high blood pressure, abnormal levels of lipid, obstructive sleep apnea, heart disease * Have at least one unsuccessful attempt to lose weight by dieting Exclusion Criteria: * Have a self-reported change in body weight \>5 kilograms (kg) (11 pounds) within 90 days before screening * Have a prior or planned surgical treatment for obesity * Have type 1 diabetes or type 2 diabetes * Have a family or personal history of medullary thyroid carcinoma (MTC) or multiple endocrine neoplasia syndrome type 2 (MEN-2) * Have had within the past 90 days before screening: * heart attack * stroke * hospitalization for unstable angina or heart failure * Have New York Heart Association Functional Classification Class IV congestive heart failure * Have a history of chronic or acute pancreatitis * Have taken weight loss drugs, including over-the counter medications within 90 days prior to screening
Study locations
35 registered sites.
Argentina · Canada · United States. Showing up to 24 locations stored in the fast local snapshot.
Arizona Research Center
Phoenix, Arizona, United States
Care Access - Huntington Beach
Huntington Beach, California, United States
Los Angeles Institute for Metabolic Research
Los Angeles, California, United States
New Horizon Research Center
Miami, Florida, United States
Encore Medical Research - Weston
Weston, Florida, United States
Pacific Diabetes & Endocrine Center
Honolulu, Hawaii, United States
Monroe Biomedical Research - Louisville
Louisville, Kentucky, United States
Brigham and Women's Hospital Diabetes Program
Boston, Massachusetts, United States
Great Lakes Research Group, Inc.
Bay City, Michigan, United States
NYC Research INC
Long Island City, New York, United States
Weill Cornell Medical College
New York, New York, United States
Care Access - Raleigh
Raleigh, North Carolina, United States
New Phase Research and Development
Knoxville, Tennessee, United States
Velocity Clinical Research, Dallas
Dallas, Texas, United States
Cedar Health Research - Texas Native Health
Dallas, Texas, United States
Cedar Health Research
Dallas, Texas, United States
Cedar Health Research - Fort Worth
Fort Worth, Texas, United States
Advanced Research Institute
Ogden, Utah, United States
Dominion Medical Associates, Inc.
Richmond, Virginia, United States
CAMC Institute for Academic Medicine
Charleston, West Virginia, United States
Cicemo Srl
Buenos Aires, Argentina
CARDIAMET Investigaciones Médicas
Buenos Aires, Argentina
Stat Research S.A.
Buenos Aires, Argentina
Centro de Investigaciones Metabólicas (CINME)
Buenos Aires, Argentina
Publications
Results and literature.
No PMID-linked publications were present in this registry snapshot.
Related trials
More studies on Retatrutide.
NCT IDStudyPhase / statusEnrollmentUpdated
A Study of Retatrutide (LY3437943) in Participants With Obesity and Cardiovascular Disease
Eli Lilly · Obesity · Cardiovascular Diseases
Phase 3
Completed
1,946
2026-07
A Study of Retatrutide (LY3437943) in Participants With Type 2 Diabetes Mellitus Who Have Obesity or Overweight
Eli Lilly · Type 2 Diabetes · Obesity
Phase 3
Completed
1,152
2026-07
A Study of Retatrutide (LY3437943) in Participants Who Have Obesity or Overweight and Chronic Low Back Pain
Eli Lilly · Obesity · Overweight
Phase 3
Active, not recruiting
586
2026-07
Effect of Retatrutide Compared With Placebo in Participants With Type 2 Diabetes and Moderate or Severe Renal Impairment, With Inadequate Glycemic Control on Basal Insulin, With or Without Metformin and/or SGLT2 Inhibitor (TRANSCEND-T2D-3)
Eli Lilly · Type 2 Diabetes
Phase 3
Active, not recruiting
320
2026-07
The Effect of Retatrutide Once Weekly on Cardiovascular Outcomes and Kidney Outcomes in Adults Living With Obesity (TRIUMPH-Outcomes)
Eli Lilly · Atherosclerotic Cardiovascular Disease (ASCVD) · Chronic Kidney Disease (CKD)
Phase 3
Active, not recruiting
10,000
2026-07
A Study of Retatrutide (LY3437943) Compared to Tirzepatide (LY3298176) in Adults Who Have Obesity
Eli Lilly · Obesity
Phase 3
Active, not recruiting
800
2026-07
A Master Protocol of Multiple Agents in Adults With Metabolic Dysfunction-Associated Steatotic Liver Disease (SYNERGY-Outcomes)
Eli Lilly · Metabolic Dysfunction-Associated Steatotic Liver Disease
Phase 3
Recruiting
4,500
2026-07
A Study to Evaluate the Effect of Retatrutide on Insulin Secretion and Insulin Sensitivity in Adult Participants With Type 2 Diabetes Mellitus
Eli Lilly · Diabetes Mellitus · Insulin Sensitivity
Phase 1
Active, not recruiting
95
2026-07
Related PeptideStat pages
Put the record in context.
Research pages describe evidence. Vendor pages, where available, describe independently tracked research-product listings and are not clinical recommendations.